clinical trial · NCT03838926

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

$VNDA →·phase1·recruiting·n = 42

Relapsed or Refractory Hematologic MalignanciesTrichostatin A

brief summary

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

started

Sep 27, 2018

primary completion

Dec 1, 2027

completion

Dec 1, 2027

last updated

Mar 16, 2026

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol